Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy.

doi:10.1158/1078-0432.CCR-17-1034

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Nov 2017

Beltran Himisha, Wyatt Alexander W, Chedgy Edmund C, Donoghue Adam, Annala Matti, Warner Evan W, Beja Kevin, Sigouros Michael, Mo Fan, Fazli Ladan, Collins Colin C, Eastham James, Morris Michael, Taplin Mary-Ellen, Sboner Andrea, Halabi Susan, Gleave Martin E

Abstract excerpt

Purpose: The combination of docetaxel chemotherapy and androgen deprivation therapy (ADT) has become a standard treatment for patients with metastatic prostate cancer. The recently accrued phase III CALGB 90203 trial was designed to investigate the clinical effectiveness of this treatment approach earlier in the disease. Specimens from this trial offer a unique opportunity to interrogate the acute molecular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgen Receptor Antagonists

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biopsy, Needle

Share to Combined Modality Therapy

Share to Docetaxel

Share to Neoadjuvant Therapy

Share to Neoplasm Grading

Share to Prostatectomy

Share to Taxoids

Source

Open in PubMed Open full text

Identifiers

PMID: 28842510
DOI: 10.1158/1078-0432.CCR-17-1034
PMCID: PMC5690882

Genes

ERG
FOXA1
PTEN
SPOP
TMPRSS2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy.PMID 28842510Read ↗

Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.Semantic proximity Read ↗

Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancerSemantic proximity Read ↗

Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancersSemantic proximity Read ↗

Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancerSemantic proximity Read ↗

Prognostic Expression Signature of RB1, PTEN, and TP53 Genes in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Receptor Pathway InhibitorsSemantic proximity Read ↗

Molecular mechanisms of docetaxel resistance in prostate cancerSemantic proximity Read ↗

Localized high-risk prostate cancer harbors an androgen receptor low subpopulation susceptible to HER2 inhibitionSemantic proximity Read ↗

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.Semantic proximity Read ↗

Non-Coding RNAs Set a New Phenotypic Frontier in Prostate Cancer Metastasis and Resistance.Semantic proximity Read ↗

Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation TherapySemantic proximity Read ↗

Integrating Aggressive Variant Prostate Cancer-Associated Tumor Suppressor Gene Status to Refine Prognosis and Predict Androgen-Receptor Pathway Inhibitors Response in Metastatic Hormone-Sensitive Prostate CancerSemantic proximity Read ↗

SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.